<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="1042">
  <stage>Registered</stage>
  <submitdate>25/01/2006</submitdate>
  <approvaldate>23/03/2006</approvaldate>
  <actrnumber>ACTRN12606000107527</actrnumber>
  <trial_identification>
    <studytitle>Weight Loss &amp; Cardiovascular Risk in Type 2 Diabetes Study</studytitle>
    <scientifictitle>Effect of energy restriction and exercise training on flow-mediated dilatation and oxidative stress in sedentary overweight and obese subjects with type 2 diabetes</scientifictitle>
    <utrn />
    <trialacronym>n/a</trialacronym>
  </trial_identification>
  <conditions>
    <healthcondition>Type 2 diabetes</healthcondition>
    <healthcondition>Obesity</healthcondition>
    <conditioncode>
      <conditioncode1>Metabolic and Endocrine</conditioncode1>
      <conditioncode2>Diabetes</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Diet and nutrition</conditioncode1>
      <conditioncode2>Obesity</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>12 weekdietary weight loss (energy restriction) &amp; aerobic exercise training program</interventions>
    <comparator>12 week dietary weight loss program (energy restriction)</comparator>
    <control>Placebo</control>
    <interventioncode>Lifestyle</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>1. Endothelial function (flow mediated dilatation)</outcome>
      <timepoint>Measured at week 0 (baseline) and week 12 (end of intervention).</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>2. Cardiovascular disease risk markers</outcome>
      <timepoint>Measured at week 0 (baseline) and week 12 (end of intervention).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>n/a</outcome>
      <timepoint />
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>BMI greater than 27, less than 40Type 2 diabetes.</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Beta-blocker or glucocortcoids medicationdietary supplementsregular physcial exercise.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Volunteers will be randomly allocated by computer generated sequence to study treatments.This allocation will be concealed from research staff by a locked computer file.However, due to the nature of the treatments being investigated, the sequence allocation cannot be consealed from the volunteers.</concealment>
    <sequence>volunteers will be initially blocked matched into 2 groups based on age, body mass index and gender prior to randomisation by computer generated sequence</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures>n/a</designfeatures>
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>6/03/2006</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>40</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Government body</primarysponsortype>
    <primarysponsorname>CSIRO &amp; Diabetes Aust research trust</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Charities/Societies/Foundations</fundingtype>
      <fundingname>diabetes aust research trust</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>CSIRO Human Nutrition</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <fundingsource>
      <fundingtype>Other Collaborative groups</fundingtype>
      <fundingname>Aust technology network</fundingname>
      <fundingaddress />
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>Other Collaborative groups</sponsortype>
      <sponsorname>Aust technology network</sponsorname>
      <sponsoraddress />
      <sponsorcountry>United Arab Emirates</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The principal aim of this research project is to determine the separate effects of energy restriction/weight loss and aerobic exercise training on blood vessel function in sedentary overweight and obese subjects with type 2 diabetes.

It is a secondary aim to evaluate whether physical exercise training and weight loss will enhance antioxidant capacity, reduce oxidative stress and increase nitric oxide bioavailability</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>CSIRO &amp; University of South Australia</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Grant Brinkworth</name>
      <address>Commonwealth Scientific and Industrial Research Organisation (CSIRO) Human Nutrition
PO Box 10041
Adelaide BC SA 5000</address>
      <phone>+61 8 83038830</phone>
      <fax>+61 8 8303 8899</fax>
      <email>grant.brinkworth@csiro.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Dr Grant Brinkworth</name>
      <address>Commonwealth Scientific and Industrial Research Organisation (CSIRO) Human Nutrition
PO Box 10041
Adelaide BC SA 5000</address>
      <phone>+61 8 83038830</phone>
      <fax>+61 8 8303 8899</fax>
      <email>grant.brinkworth@csiro.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>